Oracle Health Sciences announced the availability of Oracle Health Sciences OutcomeLogix On Demand 3.0 a Web-based, scalable data collection system that enables life science companies and contract research organizations (CROs) to efficiently capture accurate therapy outcome information from health care providers, as well as patients in late-stage studies.
The newest version of the solution incorporates several features that help meet increasing requirements to improve product safety and demonstrate long-term treatment efficacy. New capabilities that address the increasingly larger, geographically dispersed, and patient-centered nature of observational studies include:
Featuring a flexible, Web-based architecture, Oracle Health Sciences OutcomeLogix On Demand 3.0 can be deployed quickly and easily to large numbers of sites and patients.
Oracle Health Sciences OutcomeLogix On Demand 3.0 is part of a comprehensive portfolio of Oracle Health Sciences Cloud Applications and is powered by the Oracle Health Sciences Cloud to help customers accelerate IT deployments, reduce resources required to maintain IT infrastructure, and gain a more predictable IT spending pattern.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.